Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note
Section:
 
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

DIM Price Targets Summary
Sartorius Stedim Biotech SA

Wall Street analysts forecast DIM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DIM is 219.96 EUR with a low forecast of 135.34 EUR and a high forecast of 325.5 EUR.

DIM Lowest Forecast
Wall Street Target
135.34 EUR
23% Downside
DIM Average Forecast
Wall Street Target
219.96 EUR
26% Upside
DIM Highest Forecast
Wall Street Target
325.5 EUR
86% Upside
Lowest
Price Target
135.34 EUR
23% Downside
Average
Price Target
219.96 EUR
26% Upside
Highest
Price Target
325.5 EUR
86% Upside
Sartorius Stedim Biotech SA Competitors:
Price Targets
1SXP
SCHOTT Pharma AG & Co KgaA
32% Upside
300759
Pharmaron Beijing Co Ltd
6% Upside
BANB
Bachem Holding AG
22% Upside
ONT
Oxford Nanopore Technologies PLC
45% Upside
1SXP
SCHOTT Pharma AG & Co KgaA
32% Upside
300759
Pharmaron Beijing Co Ltd
6% Upside
BANB
Bachem Holding AG
22% Upside
ONT
Oxford Nanopore Technologies PLC
45% Upside
WST
West Pharmaceutical Services Inc
15% Upside
PSNL
Personalis Inc
107% Upside
IQV
IQVIA Holdings Inc
27% Upside
MRVI
Maravai LifeSciences Holdings Inc
90% Upside

Revenue
Forecast

Revenue Estimate
Sartorius Stedim Biotech SA

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's revenue is 15%. The projected CAGR for the next 3 years is 7%.

15%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sartorius Stedim Biotech SA

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's operating income is 11%. The projected CAGR for the next 3 years is 17%.

11%
Past Growth
17%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sartorius Stedim Biotech SA

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's net income is 13%. The projected CAGR for the next 3 years is 20%.

13%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

See Also

Summary
DIM intrinsic value, competitors valuation, and company profile.
DCF Valuation
DIM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DIM stock valuation using valuation multiples.
Wall Street Estimates
DIM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DIM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DIM's stock price target?
Price Target
219.96 EUR

According to Wall Street analysts, the average 1-year price target for DIM is 219.96 EUR with a low forecast of 135.34 EUR and a high forecast of 325.5 EUR.

What is Sartorius Stedim Biotech SA's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's revenue is 15%. The projected CAGR for the next 3 years is 7%.

What is Sartorius Stedim Biotech SA's Operating Income forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's operating income is 11%. The projected CAGR for the next 3 years is 17%.

What is Sartorius Stedim Biotech SA's Net Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's net income is 13%. The projected CAGR for the next 3 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.